Search
  • mmahomed2
    • Apr 4, 2018
    • 1 min read

QB3 Biotech Pitch Summit

Valitor was among a select group of early-stage start up companies that were invited to participate in the 2018 QB3 Biotech Pitch Summit. This was an exciting opportunity to share Valitor’s science and business plan to top-tier life science investors from around the world. This event was the kick-off of our Series A fundraising, and we were thrilled but the positive reception we received from potential investors.

33 views0 comments

Recent Posts

See All

Series A financing

Valitor is proud to announce the final close of our Series A financing, co-lead by the Berkeley Catalyst Fund and ShangPharma Innovations. This round oversubscribed our initial offering, and we raised

Phase I SBIR grant from the National Cancer Institute

Valitor has been awarded a Phase I SBIR grant from the National Cancer Institute. This project will support validation of our platform technology to generate long-acting immunotherapies that can provi

© Valitor, Inc 2021

  • LinkedIn - White Circle